Stryker’s Incompass System Secures FDA Nod, Boosting Orthopaedics Innovation Strategy

Stryker Corporation (NYSE:SYK) ranks among the best set-it-and-forget-it stocks to buy. On June 25, Stryker Corporation (NYSE:SYK) announced that its Incompass Total Ankle System, intended for patients with severe rheumatoid, post-traumatic, or degenerative arthritis-related ankle joint damage, received FDA 510(k) clearance.

Stryker’s Incompass System Secures FDA Nod, Boosting Orthopaedics Innovation Strategy

The Incompass system integrates Adaptis Boney Ingrowth Technology and revised instrumentation to facilitate long-term fixation, surgical flexibility, and optimized workflow. According to the company, data from 100,000 clinical cases and over 85,000 CT scans were used in guiding the system’s development.

Additionally, in support of the company’s strategic direction, Stryker Corporation (NYSE:SYK) shareholders recently approved revisions to key incentive plans, such as the 2008 Employee Stock Purchase Plan and the 2011 Long-Term Incentive Plan.

Founded in 1981, Stryker Corporation (NYSE:SYK) is a leading provider of medical technology products and services. Its business operations are divided into three primary divisions: Orthopaedics, MedSurg, and Neurotechnology and Spine.

While we acknowledge the potential of SYK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.